Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets.
The aim of this study was to define metabolic signaling pathways that mediate DNA synthesis and cell cycle progression in adult rodent islets to devise strategies to enhance survival, growth, and proliferation. Since previous studies indicated that glucose-stimulated activation of mammalian target of rapamycin (mTOR) leads to [3H]thymidine incorporation and that mTOR activation is mediated, in part, through the K(ATP) channel and changes in cytosolic Ca2+, we determined whether glyburide, an inhibitor of K(ATP) channels that stimulates Ca2+ influx, modulates [3H]thymidine incorporation. Glyburide (10-100 nm) at basal glucose stimulated [3H]thymidine incorporation to the same magnitude as elevated glucose and further enhanced the ability of elevated glucose to increase [3H]thymidine incorporation. Diazoxide (250 microm), an activator of KATP channels, paradoxically potentiated glucose-stimulated [3H]thymidine incorporation 2-4-fold above elevated glucose alone. Cell cycle analysis demonstrated that chronic exposure of islets to basal glucose resulted in a typical cell cycle progression pattern that is consistent with a low level of proliferation. In contrast, chronic exposure to elevated glucose or glyburide resulted in progression from G0/G1 to an accumulation in S phase and a reduction in G2/M phase. Rapamycin (100 nm) resulted in an approximately 62% reduction of S phase accumulation. The enhanced [3H]thymidine incorporation with chronic elevated glucose or glyburide therefore appears to be associated with S phase accumulation. Since diazoxide significantly enhanced [3H]thymidine incorporation without altering S phase accumulation under chronic elevated glucose, this increase in DNA synthesis also appears to be primarily related to an arrest in S phase and not cell proliferation.
Kwon
Guim
G
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Marshall
Connie A
CA
Liu
Hui
H
Pappan
Kirk L
KL
Remedi
Maria S
MS
McDaniel
Michael L
ML
D000818:Animals; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism; D002453:Cell Cycle; D002455:Cell Division; D049109:Cell Proliferation; D002478:Cells, Cultured; D003600:Cytosol / Q000378:metabolism; D003981:Diazoxide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D016195:G2 Phase; D005947:Glucose / Q000378:metabolism*; D005905:Glyburide / Q000737:chemistry / Q000378:metabolism; D007515:Islets of Langerhans / Q000166:cytology*; D008297:Male; D009543:Nifedipine / Q000494:pharmacology; D011188:Potassium / Q000737:chemistry; D015221:Potassium Channels / Q000737:chemistry*; D011494:Protein Kinases / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016196:S Phase; D020123:Sirolimus / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D013936:Thymidine / Q000378:metabolism
D015221:Potassium Channels; D011494:Protein Kinases; D058570:TOR Serine-Threonine Kinases; D009543:Nifedipine; D005947:Glucose; D003981:Diazoxide; D011188:Potassium; D005905:Glyburide; D002118:Calcium; D013936:Thymidine; D020123:Sirolimus